Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

BACKGROUND: Two antifibrotic drugs, nintedanib and pirfenidone, are available for treatment of idiopathic pulmonary fibrosis (IPF). Although efficacy and adverse events have been well studied, little is known about patient experiences with these drugs. We aimed to systematically and quantitatively e...

Descripción completa

Detalles Bibliográficos
Autores principales: Moor, C. C., Mostard, R. L. M., Grutters, J. C., Bresser, P., Aerts, J. G. J. V., Dirksen, C. D., Kimman, M. L., Wijsenbeek, M. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376884/
https://www.ncbi.nlm.nih.gov/pubmed/32703201
http://dx.doi.org/10.1186/s12931-020-01458-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376884/
https://www.ncbi.nlm.nih.gov/pubmed/32703201
http://dx.doi.org/10.1186/s12931-020-01458-1

Ejemplares similares